Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | CCNC | P24863 | 2/20 | 0.30 |
| ▸ | CDK8 | P49336 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12887080 | 0.90 | ALOX5 (0.31) | — | |
| SCHEMBL13670716 | 0.86 | — | — | |
| SCHEMBL12887107 | 0.85 | CYP11B1 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK9 | |
| SCHEMBL12887356 | 0.85 | CYP11B1 (0.37) | CYP11B1 | |
| SCHEMBL12887259 | 0.85 | TNF (0.35) | NPC1RAB9ASLC22A12 | |
| SCHEMBL12887173 | 0.83 | CYP11B2 (0.46) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK9 | |
| SCHEMBL12887116 | 0.82 | CYP17A1 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK9 | |
| SCHEMBL12887106 | 0.82 | CYP11B1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK9 | |
| SCHEMBL1102610 | 0.82 | MAPK10 (0.33) | CYP11B1MAPK10 | |
| SCHEMBL12886825 | 0.82 | CYP11B2 (0.36) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888863-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2011-02-15 | — | — | US | disclosed |
| US-7888863-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2011-02-15 | — | — | US | disclosed |
| US-20090260686-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090260686-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090260686-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, FZD7 | CYP17A1 1660/4885CYP19A1 824/4885CYP11B1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.